Ghrelin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-25. Numbers and descriptions here follow the published literature rather than marketing material.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
The mechanism describing the formation of the ozone layer was described by British mathematician and geophysicist Sydney Chapman in 1930, and is known as the Chapman cycle or ozone–oxygen cycle. Molecular oxygen absorbs high energy sunlight in the UV-C region, at wavelengths shorter than about 240 nm. Radicals produced from the homolytically split oxygen molecules combine with molecular oxygen to form ozone. Ozone in turn is photolyzed much more rapidly than molecular oxygen as it has a stronger absorption that occurs at longer wavelengths, where the solar emission is more intense. Ozone (O3) photolysis produces O and O2. The oxygen atom product combines with atmospheric molecular oxygen to reform O3, releasing heat. The rapid photolysis and reformation of ozone heat the stratosphere, resulting in a temperature inversion. This increase of temperature with altitude is characteristic of the stratosphere; its resistance to vertical mixing means that it is stratified. Within the stratosphere temperatures increase with altitude (see temperature inversion); the top of the stratosphere has a temperature of about 270 K (−3°C or 26.6°F). This vertical stratification, with warmer layers above and cooler layers below, makes the stratosphere dynamically stable: there is no regular convection and associated turbulence in this part of the atmosphere. However, exceptionally energetic convection processes, such as volcanic eruption columns and overshooting tops in severe supercell thunderstorms, may carry convection into the stratosphere on a very local and temporary basis.
=== Immune system and infection === Hyperglycemia has been linked to increased susceptibility to a range of infectious diseases. This susceptibility can be attributed to the impairment of the immune system's response, which is often compromised in hyperglycemic conditions. Hyperglycemia also leads to biochemical changes in the body; both of these factors result in increased severity of respiratory infections and vulnerability to pathogens. Hyperglycemic individuals face the most pronounced risk from such types of ailments, including tuberculosis, the flu, and COVID-19. These risks can be compounded even further by the effects of physiological stress. Importantly, hyperglycemia affects the function of neutrophils, which are white blood cells responsible for responding to infection. In hyperglycemic individuals, the ability for neutrophils to move toward infection sites, ingest bacteria, and kill them are often impaired, leading to reduced effectiveness in combating infections. Hyperglycemia also creates microbiological changes within the body: hyperglycemia can lead to rapid changes in blood pH and cell viscosity, weakening the cells and making it more conducive for infectious agents to thrive and dampen inflammatory responses. This is because hyperglycemia impacts a few factors such as the microenvironment of immune cells, or even bacteria's supply of energy, adding on stress to the bacterial proliferation metabolism. The chronic inflammatory state induced by high glucose levels can also lead to dysfunction in various parts of the immune system.
== Associated clinical conditions == Hyperaldosteronism is abnormally increased levels of aldosterone, while hypoaldosteronism is abnormally decreased levels of aldosterone. A measurement of aldosterone in blood may be termed a plasma aldosterone concentration (PAC), which may be compared to plasma renin activity (PRA) as an aldosterone-to-renin ratio.
Sources: en.wikipedia.org
Very common (>10% of people with pregabalin): dizziness, drowsiness. Common (1–10% of people with pregabalin): peripheral edema, blurred vision, diplopia, increased appetite and subsequent weight gain, euphoria, confusion, vivid dreams, changes in libido (increase or decrease), irritability, ataxia, attention changes, feeling high, memory impairment, tremor, dysarthria, paresthesia, vertigo, dry mouth, constipation, nausea, vomiting, flatulence, erectile dysfunction, fatigue, feelings of drunkenness, abnormal walking, asthenia, nasopharyngitis, increased creatine kinase level. Infrequent (0.1–1% of people with pregabalin): depression, lethargy, agitation, anorgasmia, hallucinations, myoclonus, hypoaesthesia, hyperaesthesia, tachycardia, hypersalivation, hypoglycemia, excessive sweating, flushing, rash, muscle cramp, myalgia, arthralgia, urinary incontinence, dysuria, thrombocytopenia, kidney calculus. Rare (<0.1% of people with pregabalin): neutropenia, first-degree heart block, hypotension, hypertension, pancreatitis, dysphagia, oliguria, rhabdomyolysis, suicidal thoughts or behavior. Cases of recreational use, with associated adverse effects, have been reported.
== Carbamino compounds in blood == The concentration of carbamate (HbCO2) was estimated in oxygenated and deoxygenated red blood cells of adult and fetal humans. The estimation was carried out at a constant pressure of carbon dioxide (PCO2 = 40 mm Hg) and varied pH levels of the serum. The bicarbonate concentration in the red cells was calculated using the Donnan ratio for chloride and bicarbonate ions. Based on this figure, the carbamate concentration was determined by subtracting the bicarbonate concentration and dissolved CO2 from the total CO2 concentration. Deoxygenated fetal red cells contain more HbCO2 than deoxygenated adult red cells at a given pH value in the red cell. Upon oxygenation, HbCO2 decreased in both types of erythrocytes to values lower than in deoxygenated cells, at a constant pH. The fraction of 'oxylabile carbamate' (-ΔHbCO2/ΔHbO2) at a red cell pH of 7·2 and a PCO2 of 40 mm Hg is 0·117 in fetal and 0·081 in adult erythrocytes. The apparent carbamate equilibrium constants (K'c and K'z) were calculated from the fraction of moles carbamate formed per Hb monomer (moles CO2/mole Hbi). These constants can be used to estimate the carbamate concentration in normal adult and fetal blood. In adult red cells, the first apparent dissociation constant of carbonic acid is significantly higher in oxygenated (-log10K'1 = pK'1 = 6·10) than in deoxygenated (pK'1 = 6·12) red cells, whereas in fetal red cells, the difference is smaller and statistically not significant.
Synovial cavity: all diarthroses have the characteristic space between the bones that is filled with synovial fluid. Joint capsule: the fibrous capsule, continuous with the periosteum of articulating bones, surrounds the diarthrosis and unites the articulating bones; the joint capsule consists of two layers - (1) the outer fibrous membrane that may contain ligaments and (2) the inner synovial membrane that secretes the lubricating, shock absorbing, and joint-nourishing synovial fluid; the joint capsule is highly innervated, but without blood and lymph vessels, and receives nutrition from the surrounding blood supply via either diffusion (slow), or via convection (fast, more efficient), induced through exercise. Articular cartilage: the bones of a synovial joint are covered by a layer of hyaline cartilage that lines the epiphyses of the joint end of the bone with a smooth, slippery surface that prevents adhesion; articular cartilage functions to absorb shock and reduce friction during movement. Many, but not all, synovial joints also contain additional structures:
Sources: en.wikipedia.org
GnRH antagonists have an immediate onset of action leading to a fast and profound suppression of testosterone and are therefore especially valuable in the treatment of patients with prostate cancer, where fast control of disease is needed. The GnRH antagonist abarelix was withdrawn from the United States market in 2005 and is now only marketed in Germany for use in patients with symptomatic prostate cancer. Degarelix is a GnRH antagonist that is approved for use in patients with advanced hormone-sensitive prostate cancer throughout Europe and also in the United States.
Melanie Ann Stansbury (born January 31, 1979) is an American politician and former ecology instructor serving as the U.S. representative for New Mexico's 1st congressional district since 2021. The district includes the majority of Albuquerque and most of its suburbs. A Democrat, Stansbury previously served as a member of the New Mexico House of Representatives for the 28th district from 2019 to 2021.
=== Circadian rhythm === Wild-type flies show an activity rhythm with a frequency of about a day (24 hours). Benzer and others found mutants with faster and slower rhythms, as well as broken rhythms—flies that move and rest in random spurts. Work over the following 30 years has shown that these mutations (and others like them) affect a group of genes and their products that form a biochemical or biological clock. This clock is found in a wide range of fly cells, but the clock-bearing cells that control activity are several dozen neurons in the fly's central brain. The Nobel Prize in Physiology or Medicine for 2017 was awarded to Jeffrey C. Hall, Michael Rosbash, Michael W. Young for their works using fruit flies in understanding the "molecular mechanisms controlling the circadian rhythm".
== Legal status == As of March 2022, the European Commission has taken new measures to control the psychoactive substance of 3-CMC. This decision is based on a risk assessment conducted by the EU Drugs Agency (EMCDDA) in November 2021. Since 3-CMC was prohibited in China (October 2015), it was found that most of the production was manufactured in India and little of the substance supply originates from inside Europe. Several European countries were ahead of the European Commission report by (generically) controlling the substance. Nowadays, in almost all countries 3-CMC is prohibited.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Keep the powder dry, protected from light, and at minus 20 degrees Celsius or lower. A desiccant and a sealed vial limit moisture uptake. Let the vial reach room temperature before opening to reduce condensation.